Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$8.29 USD
+0.03 (0.36%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $8.28 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.29 USD
+0.03 (0.36%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $8.28 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
by Zacks Equity Research
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
Maravai (MRVI) Advances in RNA Research With New Collaboration
by Zacks Equity Research
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Are Options Traders Betting on a Big Move in Maravai LifeSciences (MRVI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.
Zynex Inc. (ZYXI) Q3 Earnings Match Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0% and 0.84%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
PetIQ (PETQ) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ZimVie Inc. (ZIMV) Stock Jumps 20.6%: Will It Continue to Soar?
by Zacks Equity Research
ZimVie Inc. (ZIMV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm (VAPO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vapotherm (VAPO) delivered earnings and revenue surprises of -9.76% and 4.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Vapotherm (VAPO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Maravai LifeSciences Holdings, Inc. (MRVI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 Earnings Beat Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 15.63% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Maravai LifeSciences (MRVI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Q2 Earnings Meet Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie
by Zacks Equity Research
Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.
5 Cheap Healthcare Stocks in 2022
by Tracey Ryniec
Looking for value stocks? Healthcare has been ignored over the last year.
Implied Volatility Surging for Maravai LifeSciences (MRVI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Maravai LifeSciences (MRVI) stock based on the movements in the options market lately.
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 25.58% and 6.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q1 top- and bottom-line results reflect negative impact of supply chain constraints and consequences of the Respironics field action.
Wall Street Analysts See a 38% Upside in Maravai LifeSciences Holdings, Inc. (MRVI): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 38.1% upside potential for Maravai LifeSciences Holdings, Inc. (MRVI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.